Immunotherapies in Diabetes Mellitus Type 1

Medical Clinics of North America

Volumn 96, Issue 3, 2012, Pages 621-634

  Gupta, Smita ^a  

^a NONE   (United States)

Author keywords

Diabetes mellitus type 1; Immunomodulators; Immunosuppressants; Immunotherapies; Transplantation

Indexed keywords

ABATACEPT; AUTOANTIBODY; AZATHIOPRINE; BASILIXIMAB; BCG VACCINE; CALCITRIOL; CD3 ANTIBODY; CYCLOSPORIN; DACLIZUMAB; DIAMYD; DIAPEP 277; ETANERCEPT; EXENDIN 4; GLUTAMIC ACID DECARBOXYLASE ALUM; INSULIN; LANSOPRAZOLE; MILK PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OMEGA 3 FATTY ACID; OTELIXIZUMAB; PEPTIDE; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SITAGLIPTIN; TEPLIZUMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ABSENCE OF SIDE EFFECTS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B LYMPHOCYTE; BERRY; BETA CHAIN; BREAST FEEDING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL REGENERATION; CEREAL; DENDRITIC CELL; DIET; DRUG WITHDRAWAL; EFFECTOR CELL; ENVIRONMENTAL FACTOR; FEVER; FRUIT; GASTROINTESTINAL DISEASE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GINGIVA HYPERPLASIA; HEADACHE; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERTRICHOSIS; HYPOGLYCEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; LOW DRUG DOSE; LUPUS VULGARIS; LYMPHOMA; MILK; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTAKE; RASH; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RISK; RISK FACTOR; SIDE EFFECT; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VASCULITIS; VIRUS REACTIVATION; WEGENER GRANULOMATOSIS;

EID: 84862315128     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.04.008     Document Type: Review

References (82)

1. Phillips B., Trucco M., Giannoukakis N. Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?. Clin Dev Immunol 2011, 2011:432016.
2. Bach J.F. Infections and autoimmune diseases. J Autoimmun 2005, 25(Suppl):74-80.
3. Knip M. Can we predict type 1 diabetes in the general population?. Diabetes Care 2002, 25:623-625.
4. Wenzlau J.M., Juhl K., Yu L., et al. The cation transporter ZnT8 (Slc30A8) is a major antigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007, 104:17040-17045.
5. Knip M. Should we screen for risk of type 1 diabetes?. Diabetes Care 2008, 31:622-623.
6. Bingley P.J., Gale E.A. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006, 49:881-890.
7. Like A.A., Weringer E.J., Holdash A., et al. Adoptive transfer of autoimmune diabetes in biobreeding/Worcester (BB/W) inbred and hybrid rats. J Immunol 1985, 134:1583-1587.
8. Bresson D., von Herrath M. Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside. Diabetes Care 2009, 32(10):1753-1768.
9. Steffes M.W., Sibley S., Jackson M., et al. Beta cell function and the development of diabetes related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003, 26(3):832-836.
10. Rewers M., Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care 2009, 32(10):1769-1782.
11. Patterson C.C., Dahlquist G.G., Gyurus E., et al. Incidence trends in for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20; multicentre prospective registration study. Lancet 2009, 373:2027-2033.
12. Ziegler A.-G., Hummel M., Schenker M., et al. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999, 48:460-468.
13. Kimpimaki T., Kupila A., Hamalainen A.M., et al. The first signs of β-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish type 1 diabetes prediction and prevention Study. J Clin Endocrinol Metab 2001, 86:4782-4788.
14. Karges W., Hammond-McKibben D., Cheung R.K., et al. Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk based IDDM prevention trial. Diabetes 1997, 46:557-564.
15. Malkani S., Nompleggi D., Hansen J.W., et al. Dietary cow's milk protein does not alter the frequency of diabetes in the BB rat. Diabetes 1997, 46:1133-1140.
16. Virtanen S.M., Knip M. Nutritional risk predictors of β cell autoimmunity and type 1 diabetes at a young age. Am J Clin Nutr 2003, 78:1053-1067.
17. Knip M., Virtanen S.M., Akerblom H.K. Infant feeding and risk of type 1 diabetes. Am J Clin Nutr 2010, 91(Suppl):1506S-1513S.
18. Knip M., Virtanen S.M., Becker D., TRIGR Study Group, et al. Early feeding and risk of type 1 diabetes: experiences from the Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk (TRIGR). Am J Clin Nutr 2011, 94(Suppl 6):1814S-1820S.
19. TRIGR Study Group, Akerblom H.K., Krischer J., et al. The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) study: recruitment, intervention and follow-up. Diabetologia 2011, 54(3):627-633.
20. Ziegler A.G., Schmid S., Huber D., et al. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003, 290(13):1721-1728.
21. Holmberg H., Wahlberg J., Vaarala O., et al. Short duration of breast feeding as a risk factor for beta cell auto-antibodies in 5 year old children from the general population. Br J Nutr 2007, 97:111-116.
22. The EURODIAB Substudy 2 Study Group. Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. Diabetologia 1999, 42(1):51-54.
23. Hyppönen E., Läärä E., Reunanen A., et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358(9292):1500-1503.
24. Bizzarri C., Pitocco D., Napoli N., IMDIAB Group, et al. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care 2010, 33(9):1962-1963.
25. Norris J.M., Yin X., Lamb M.M., et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 2007, 298(12):1420-1428.
26. Sosenko J.M., Palmer J.P., Greenbaum C.J., et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006, 29(3):643-649.
27. Gale E.A., Bingley P.J., Emmett C.L., European Nicotinamide Diabetes Intervention Trial (ENDIT) Group, et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363(9413):925-931.
28. Diabetes Prevention Trial-Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002, 346:1685-1691.
29. Bergerot I., Fabien N., Maguer V., et al. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun 1994, 7:655-663.
30. Polanski M., Melican N.S., Zhang J., et al. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun 1997, 10:339-346.
31. Ploix C., Bergerot I., Fabien N., et al. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes. Diabetes 1998, 47:39-44.
32. von Herrath M.G., Dyrberg T., Oldstone M.B. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest 1996, 98:1324-1331.
33. Skyler J.S., Krischer J.P., Wolfsdorf J., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2005, 28(5):1068-1076.
34. Vehik K., Cuthbertson D., Ruhlig H., DPT-1, TrialNet Study Groups, et al. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care 2011, 34(7):1585-1590.
35. Näntö-Salonen K., Kupila A., Simell S., et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008, 372(9651):1746-1755.
36. Achenbach P., Barker J., Bonifacio E., Pre-POINT Study Group Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 2008, 8(2):87-93.
37. Stiller C.R., Dupré J., Gent M., et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984, 223(4643):1362-1367.
38. Dupré J., Stiller C.R., Gent M., et al. Effects of immunosuppression with cyclosporine in insulin-dependent diabetes mellitus of recent onset: the Canadian open study at 44 months. Transplant Proc 1988, 20(3 Suppl 4):184-192.
39. Chase H.P., Butler-Simon N., Garg S.K., et al. Cyclosporine A for the treatment of new-onset insulin-dependent diabetes mellitus. Pediatrics 1990, 85(3):241-245.
40. Stiller C.R., Dupre J., Gent M., et al. Effects of cyclosporine in recent-onset juvenile type 1 diabetes: impact of age and duration of disease. J Pediatr 1987, 111(6 Pt 2):1069-1072.
41. Silverstein J., Maclaren N., Riley W., et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988, 319(10):599-604.
42. Cook J.J., Hudson I., Harrison L.C., et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 1989, 38(6):779-783.
43. Harrison L.C., Colman P.G., Dean B., et al. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 1985, 34(12):1306-1308.
44. Chatenoud L., Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007, 7(8):622-632.
45. Herold K.C., Gitelman S.E., Masharani U., et al. A single course of anti-CD3 monoclonal antibody hOKT3g1 (Ala-Ala) results in improvement in C peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54(6):1763-1769.
46. Herold K.C., Hagopian W., Auger J.A., et al. Anti CD3 monoclonal antibody in new onset type 1 diabetes mellitus. N Engl J Med 2002, 346(22):1692-1698.
47. Sherry N., Hagopian W., Ludvigsson J., et al. Teplizumab for treatment of type 1 diabetes (Protégé study):1-year results from a randomised placebo-controlled trial. Lancet 2011, 378:487.
48. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., et al. Insulin needs after CD3 antibody therapy in new onset type 1 diabetes. N Engl J Med 2005, 352(25):2598-2608.
49. Keymeulen B., Walter M., Mathieu C., et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010, 53(4):614-623.
50. Orban T., Bundy B., Becker D.J., Type 1 Diabetes TrialNet Abatacept Study Group, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378(9789):412-419.
51. Mastrandrea L., Yu J., Behrens T., et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009, 32(7):1244-1249.
52. Falcone M., Lee J., Patstone G., et al. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in non obese diabetic mice. J Immunol 1998, 179:1004-1012.
53. Bour-Jordan H., Bluestone J.A. B cell depletion: a novel therapy for autoimmune diabetes?. J Clin Invest 2007, 117(12):3642-3645.
54. Serreze D.V., Chapman H.D., Varnum D.S., et al. B lymphocytes are essential for the initiation of T-cell mediated autoimmune diabetes: analysis of a new " speed congenic" stock of NOD.Ig mu null mice. J Exp Med 1996, 184:2049-2053.
55. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., et al. Rituximab, B-lymphocyte depletion, and preservation of beta cell function. N Engl J Med 2009, 361(22):2143-2152.
56. Gottlieb P.A., Quinlan S., Krause-Steinrauf H., et al. Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010, 33(4):826-832.
57. Sobel D.O., Ahvazi B. Alpha-interferon inhibits the development of diabetes in NOD mice. Diabetes 1998, 47(12):1867-1872.
58. Rother K.I., Brown R.J., Morales M.M., et al. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Diabetes Care 2009, 32(7):1250-1255.
59. Sumpter K.M., Adhikari S., Grishman E.K., et al. Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes. Pediatr Diabetes 2011, 12(7):656-667.
60. Ogawa N., Minamimura K., Kodaka T., et al. Short administration of polyclonal anti-T cell antibody (ALS) in NOD mice with extensive insulitis prevents subsequent development of autoimmune diabetes. J Autoimmun 2006, 26(4):225-231.
61. Simon G., Parker M., Ramiya V., et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 2008, 57(2):405-414.
62. Tian J., Clare-Salzler M., Herschenfeld A., et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996, 2(12):1348-1353.
63. Tisch R., Liblau R.S., Yang X.D., et al. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998, 47(6):894-899.
64. Agardh C.D., Cilio C.M., Lethagen A., et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005, 19(4):238-246.
65. Bekris L.M., Jensen R.A., Lagerquist E., et al. GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination. Diabet Med 2007, 24(5):521-526.
66. Ludvigsson J., Faresjö M., Hjorth M., et al. GAD treatment and insulin secretion in recent onset type 1 diabetes. N Engl J Med 2008, 359(18):1909-1920.
67. Wherrett D.K., Bundy B., Becker D.J., Type 1 Diabetes TrialNet GAD Study Group, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011, 378(9788):319-327.
68. Ludvigsson J., Krisky D., Casas R., et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012, 366(5):433-442.
69. Raz I., Avron A., Tamir M., et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 2007, 23(4):292-298.
70. Raz I., Elias D., Avron A., et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001, 358(9295):1749-1753.
71. Huurman V.A., Decochez K., Mathieu C., et al. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007, 23(4):269-275.
72. Lazar L., Ofan R., Weintrob N., et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007, 23(4):286-291.
73. Buzzetti R., Cernea S., Petrone A., DiaPep Trialists Group, et al. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. Diabetes 2011, 60(11):3067-3072.
74. Sherry N.A., Chen W., Kushner J.A., et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibodies by enhancing recovery of β-cells. Endocrinology 2007, 148:5136-5144.
75. Hadjiyanni I., Baggio L.L., Poussier P., et al. Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 2008, 149:1338-1349.
76. Kim S.J., Nian C., Doudet D.J., et al. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 2009, 58:641-651.
77. Blandino-Rosano M., Perez-Arana G., Mellado-Gil J.M., et al. Anti-proliferative effect of pro-inflammatory cytokines in cultured β-cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide-1. J Mol Endocrinol 2008, 41:35-44.
78. Rother K.I., Spain L.M., Wesley R.A., et al. Effects of exenatide alone and in combination with daclizumab on β-cell function in long-standing type 1 diabetes. Diabetes Care 2009, 32:2251-2257.
79. Bosi E. Time for testing incretin therapies in early type 1 diabetes?. J Clin Endocrinol Metab 2010, 95(6):2607-2609.
80. Voltarelli J.C., Couri C.E., Stracieri A.B., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007, 297(14):1568-1576.
81. Couri C.E., Oliveira M.C., Stracieri A.B., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009, 301(15):1573-1579.
82. Gitelman S.E., Haller M.J., Schatz D. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009, 302(6):624. [author reply: 624-5].